title: Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly.
abstract: The pharmacokinetics and pharmacodynamics of a single oral dose benazepril.HCl 10 mg have been studied in 15 healthy volunteers aged 65 to 80 y. The kinetics of unchanged benazepril and its active metabolite benazeprilat did not differ significantly in males and females, so the combined kinetic data from all 15 elderly subjects were compared with a historical control group of 19-32 year-old healthy men treated in the same way. The disposition of benazepril was not affected by age. The time to maximum plasma concentration, tmax (0.5 h) and elimination half-life (0.6 h) in the elderly were the same as in young subjects. The kinetics of benazeprilat was slightly changed in the elderly; although its tmax (1.5 h) was not affected, Cmax and the AUC were 20-40% greater. The elimination half-life of benazeprilat during the first 24 h after dosing in the elderly was increased by about 20% to 3.2 h. The renal plasma clearance of benazeprilat (18.1 ml.min-1) was about 20% smaller than in the young subjects. An average of 18.5% of the dose was recovered as benazeprilat in the 24 h urine from the elderly subjects, which was similar to the recovery in the young subjects. Both benazepril and benazeprilat were highly bound to serum proteins (96 and 95%, respectively). Mean systolic and diastolic blood pressures in the elderly were reduced by a maximum of 37/16 mm Hg at 6 h, in association with a small rise in pulse rate. Treatment was generally well tolerated.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Research and Development Department, CIBA-GEIGY Limited, Basle, Switzerland.
authors.forename: G
authors.initials: G
authors.lastname: Kaiser
authors.forename: R
authors.initials: R
authors.lastname: Ackermann
authors.forename: W
authors.initials: W
authors.lastname: Dieterle
authors.forename: C J
authors.initials: CJ
authors.lastname: Durnin
authors.forename: J
authors.initials: J
authors.lastname: McEwen
authors.forename: K
authors.initials: K
authors.lastname: Ghose
authors.forename: A
authors.initials: A
authors.lastname: Richens
authors.forename: I B
authors.initials: IB
authors.lastname: Holmes
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D001552:Benzazepines / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D001798:Blood Proteins / Q000378:metabolism; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001552:Benzazepines; D001798:Blood Proteins; C044946:benazepril